News >

Key Trials Warrant Consideration in Early-Stage Pancreatic Cancer Paradigm

Caroline Seymour
Published: Wednesday, Mar 13, 2019

Dr Nilofer S. Azad

Nilofer S. Azad, M
The incidence of pancreatic cancer is on the rise—a phenomenon that can only be counteracted by better diagnostics and therapeutic strategies, explained Nilofer Saba Azad, MD, an associate professor of oncology at Johns Hopkins Medicine.

However, data from 3 recent pivotal trials have influenced practice and/or warrant consideration when treating patients with localized disease, said Azad.

PREOPANC-1

Historically, the standard of care for patients with resectable or borderline resectable tumors has been surgery followed by adjuvant chemotherapy. Although prior studies that have suggested the benefit of neoadjuvant therapy have been mainly observational in nature, the data were enough to warrant further exploration, explained Azad.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x